Search results
Should You Pick Moderna Stock At $150 After 25% Gains In A Month?
Forbes· 9 hours agoFirstly, the U.S. FDA recently approved Moderna’s respiratory syncytial virus vaccine, making it the...
Pfizer (NYSE:PFE) Trading 0.3% Higher
ETF DAILY NEWS· 1 day agoPfizer Inc. (NYSE:PFE – Get Free Report) traded up 0.3% during mid-day trading on Tuesday . The company traded as high as $29.73 and last traded at $29.41. 9,834,266 shares ...
mRESVIA’s FDA approval paves the way for mRNA vaccines across multiple indications
Clinical Trials Arena via Yahoo Finance· 1 day agoThis approval represents a significant development in the field and is likely to...results from the...
FDA advisers urge targeting JN.1 strain in recipe for fall's COVID vaccines - ABC17NEWS
ABC17 NEWS· 2 days agoBy LAURAN NEERGAARD AP Medical Writer WASHINGTON (AP) — Government advisers say it’s time to update the recipe for the COVID-19 vaccines Americans will ...
COVID shots should target JN.1, KP.2 subvariants in 2024-25 campaign, US FDA staff says
Reuters· 4 days agoVaccine makers should consider targeting one of the currently dominant JN.1 variants and...
Is a Giant Short Squeeze Brewing in Novavax (NVAX) Stock?
InvestorPlace· 1 day agoVaccine maker Novavax (NASDAQ:NVAX) saw its shares jump 18% on June 5 and another 20% in pre-market...
FDA Advisers Urge Targeting JN.1 Strain in Recipe for Fall's COVID Vaccines
US News & World Report· 2 days agoGovernment advisers Wednesday said it’s time to update the recipe for the COVID-19 vaccines Americans will receive in the fall -- targeting a version of ...
COVID Shots for JN.1 Variant Neutralize Newer Strains, Vaccine Makers Say
US News & World Report· 2 days agoFood and Drug Administration's advisers on Wednesday. The FDA panel will vote to recommend if companies should target the JN.1 variant when the companies update their vaccines
Is Pfizer the Best Dividend Stock for You?
Motley Fool via Yahoo Finance· 6 days agoThose two products represented just $2.4 billion of Pfizer's $14.9 billion in first-quarter 2024 sales. That revenue should tail off more...accumulating...
FDA Panel to Consider Updating COVID-19 Jabs for New Virus Strains
Zacks· 3 days agoShares of COVID-19 vaccine developers rose on Monday after the FDA issued briefing documents for its Vaccines and Related Biological ...
